期刊
LEUKEMIA RESEARCH
卷 35, 期 2, 页码 177-182出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2010.06.017
关键词
Myeloproliferative disorders; Treatment of polycythemia vera; JAK2(V617F) mutation; Allele burden; Splenomegaly; Myelofibrosis
资金
- Judy and William Higgins Memorial Trust of the Cancer Research and Treatment Fund, Inc. New York, NY
- Clinical Translational Science Center (CTSC) [UL1-RR024996]
In a series of 105 patients with polycythemia vera, we retrospectively determined whether the JAK2(V617F) mutation correlated with severity of disease phenotype. Higher JAK2(V617F) allele burden correlated with more advanced myelofibrosis, greater splenomegaly, and higher white blood cell count, but not with age, gender, hematocrit level, or frequency of phlebotomy prior to cytoreductive therapy. Although a subgroup at increased risk for thrombosis was not clearly defined, there was a suggestion that frequency of thrombosis increased as the JAK2(V617F) allele burden increased. The JAK2(V617F) allele burden did not change significantly in treated patients with serial JAK2 analyses. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据